FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386837745> ?p ?o ?g. }

• W4386837745 endingPage "4587" @default.
• W4386837745 startingPage "4587" @default.
• W4386837745 abstract "BRAF and MEK inhibition is a successful strategy in managing BRAF-mutant melanoma, even if the treatment-related toxicity is substantial. We analyzed the role of drug-drug interactions (DDI) on the toxicity profile of anti-BRAF/anti-MEK therapy.In this multicenter, observational, and retrospective study, DDIs were assessed using Drug-PIN software (V 2/23). The association between the Drug-PIN continuous score or the Drug-PIN traffic light and the occurrence of treatment-related toxicities and oncological outcomes was evaluated.In total, 177 patients with advanced BRAF-mutated melanoma undergoing BRAF/MEK targeted therapy were included. All grade toxicity was registered in 79% of patients. Cardiovascular toxicities occurred in 31 patients (17.5%). Further, 94 (55.9%) patients had comorbidities requiring specific pharmacological treatments. The median Drug-PIN score significantly increased when the target combination was added to the patient's home therapy (p-value < 0.0001). Cardiovascular toxicity was significantly associated with the Drug-PIN score (p-value = 0.048). The Drug-PIN traffic light (p = 0.00821) and the Drug-PIN score (p = 0.0291) were seen to be significant predictors of cardiotoxicity. Patients with low-grade vs. high-grade interactions showed a better prognosis regarding overall survival (OS) (p = 0.0045) and progression-free survival (PFS) (p = 0.012). The survival analysis of the subgroup of patients with cardiological toxicity demonstrated that patients with low-grade vs. high-grade DDIs had better outcomes in terms of OS (p = 0.0012) and a trend toward significance in PFS (p = 0.068).DDIs emerged as a critical issue for the risk of treatment-related cardiovascular toxicity. Our findings support the utility of DDI assessment in melanoma patients treated with BRAF/MEK inhibitors." @default.
• W4386837745 created "2023-09-19" @default.
• W4386837745 creator A5009242399 @default.
• W4386837745 creator A5020667912 @default.
• W4386837745 creator A5025723323 @default.
• W4386837745 creator A5029353016 @default.
• W4386837745 creator A5032411611 @default.
• W4386837745 creator A5035469274 @default.
• W4386837745 creator A5036426179 @default.
• W4386837745 creator A5040119177 @default.
• W4386837745 creator A5042989547 @default.
• W4386837745 creator A5043414157 @default.
• W4386837745 creator A5054544519 @default.
• W4386837745 creator A5060130832 @default.
• W4386837745 creator A5061265727 @default.
• W4386837745 creator A5064535822 @default.
• W4386837745 creator A5079144536 @default.
• W4386837745 date "2023-09-15" @default.
• W4386837745 modified "2023-10-17" @default.
• W4386837745 title "The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma" @default.
• W4386837745 cites W1489237918 @default.
• W4386837745 cites W1965370740 @default.
• W4386837745 cites W1983660130 @default.
• W4386837745 cites W2000001421 @default.
• W4386837745 cites W2008701998 @default.
• W4386837745 cites W2017187984 @default.
• W4386837745 cites W2019399290 @default.
• W4386837745 cites W2079216025 @default.
• W4386837745 cites W2085393530 @default.
• W4386837745 cites W2092383314 @default.
• W4386837745 cites W2099141502 @default.
• W4386837745 cites W2106543129 @default.
• W4386837745 cites W2113782793 @default.
• W4386837745 cites W2121505997 @default.
• W4386837745 cites W2121545342 @default.
• W4386837745 cites W2121823208 @default.
• W4386837745 cites W2127437403 @default.
• W4386837745 cites W2128542677 @default.
• W4386837745 cites W2136474966 @default.
• W4386837745 cites W2137221533 @default.
• W4386837745 cites W2145725580 @default.
• W4386837745 cites W2148974484 @default.
• W4386837745 cites W2150595547 @default.
• W4386837745 cites W2154748904 @default.
• W4386837745 cites W2155033804 @default.
• W4386837745 cites W2160766792 @default.
• W4386837745 cites W2160927412 @default.
• W4386837745 cites W2166262263 @default.
• W4386837745 cites W2167059308 @default.
• W4386837745 cites W2168066027 @default.
• W4386837745 cites W2168143310 @default.
• W4386837745 cites W2168711434 @default.
• W4386837745 cites W2170065082 @default.
• W4386837745 cites W2199292288 @default.
• W4386837745 cites W2228476560 @default.
• W4386837745 cites W2401259207 @default.
• W4386837745 cites W2491982852 @default.
• W4386837745 cites W2611270905 @default.
• W4386837745 cites W2612095536 @default.
• W4386837745 cites W2613818341 @default.
• W4386837745 cites W2624834472 @default.
• W4386837745 cites W2740393355 @default.
• W4386837745 cites W2752016319 @default.
• W4386837745 cites W2793817570 @default.
• W4386837745 cites W2810860620 @default.
• W4386837745 cites W2885790309 @default.
• W4386837745 cites W2891205725 @default.
• W4386837745 cites W2904792516 @default.
• W4386837745 cites W2912655931 @default.
• W4386837745 cites W2946687934 @default.
• W4386837745 cites W2989624959 @default.
• W4386837745 cites W2999915091 @default.
• W4386837745 cites W3015572296 @default.
• W4386837745 cites W3036172056 @default.
• W4386837745 cites W3128646645 @default.
• W4386837745 cites W3138574842 @default.
• W4386837745 cites W4223527921 @default.
• W4386837745 cites W4286493914 @default.
• W4386837745 cites W99605343 @default.
• W4386837745 doi "https://doi.org/10.3390/cancers15184587" @default.
• W4386837745 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37760556" @default.
• W4386837745 hasPublicationYear "2023" @default.
• W4386837745 type Work @default.
• W4386837745 citedByCount "0" @default.
• W4386837745 crossrefType "journal-article" @default.
• W4386837745 hasAuthorship W4386837745A5009242399 @default.
• W4386837745 hasAuthorship W4386837745A5020667912 @default.
• W4386837745 hasAuthorship W4386837745A5025723323 @default.
• W4386837745 hasAuthorship W4386837745A5029353016 @default.
• W4386837745 hasAuthorship W4386837745A5032411611 @default.
• W4386837745 hasAuthorship W4386837745A5035469274 @default.
• W4386837745 hasAuthorship W4386837745A5036426179 @default.
• W4386837745 hasAuthorship W4386837745A5040119177 @default.
• W4386837745 hasAuthorship W4386837745A5042989547 @default.
• W4386837745 hasAuthorship W4386837745A5043414157 @default.
• W4386837745 hasAuthorship W4386837745A5054544519 @default.
• W4386837745 hasAuthorship W4386837745A5060130832 @default.
• W4386837745 hasAuthorship W4386837745A5061265727 @default.

• next